Cipla is one of the world’s largest generic pharmaceutical companies. Its journey began in 1935 when founder, Dr. K. A. Hamied, set up an enterprise with a vision to make India self-sufficient in healthcare. Over the past 77 years, Cipla has emerged as one of the world’s most respected pharmaceutical names, not just in India but worldwide.
This global pharmaceutical company has been has been working with dedication and moving forward towards its goal to ensure that no patient shall be denied access to high quality and affordable medicine and support. Cipla’s mission is to be a leading global healthcare company which uses technology and innovation to meet everyday needs of all patients. Cipla manufactures a range of pharmaceutical and personal care products. The company offers active pharmaceutical ingredients (APIs); and formulations in therapeutic areas, such as allergy, analgesic, anti malarial, anti-infectives, cardiology, dermatology and cosmeceuticals, diabetology, gastroenterology, HIV-AIDS, hormones and steroids, iron chelators, musculoskeletal, neuropsychiatry, nutritional and ophthalmic products, oncology, respiratory, urology, and women’s health in various dosage forms. It also provides veterinary products for various animals, including companion, equine, general care, live stock, and poultry. In addition, the company offers inhaled medication and devices, such as dry powder inhalers, single-dose capsule and multi-dose dry powder inhalers, breath-actuated metered dose inhalers, non-static spacers, baby and infant masks, and nasal sprays. Further, it provides consulting, commissioning, plant engineering, and technical know-how transfer and support services.
Cipla has over 2000 products in 65 therapeutic categories available in over 40 dosage forms. Its key products include the drugs – Escitalopram (anti-depressant), Lamivudine, Fluticasone propionate. The company’s excellent Research and Development (R&D) Centre is focused on developing innovative products and drug delivery systems, giving the country and the world many ‘Firsts’. The pharmaceutical company is widely known for being the world’s largest manufacturer of antiretroviral drugs (ARVs) to fight HIV/AIDS, as measured by units produced and distributed. Roughly 40 percent of HIV/AIDS patients undergoing antiretroviral therapy worldwide take Cipla drugs. The pharmaceutical company also pioneered a three-in-one tablet called Triomune containing a fixed-dose combination (FDC) of three ARVs (Lamivudine, stavudine and Nevirapine), something difficult elsewhere because the three patents Ciplare held by different companies. Another popular fixed-dose combination is produced under the name Duovir-N. This contains Lamivudine, Zidovudine and Nevirapine. Cipla manufactures generic versions of many of the most commonly prescribed anti-retroviral medication in the market and is a highly capable manufacturer in its own right. This innovation made ARVs far more accessible and easy-to- take for patients everywhere, but particularly in poor- and middle-income countries, where the vast majority of people on anti-retroviral therapy (ART) now take such combination pills.
Cipla was among the first companies to register AIDS drugs under the US relief program PEPFAR. It has also been a major supplier of ARVs to the Clinton Foundation’s HIV/AIDS Initiative, which has negotiated low-cost drug supplies for numerous developing countries. Cipla also has a wide product range comprising antibiotics, anti-bacterial, anti-asthmatics, anthelmintic, anti-ulcerates, oncology, corticosteroids, nutritional supplements and cardiovascular drugs. The company boasts of having at least nine different prescription drugs registered with the US FDA.] Being equally active in the anti-bacterial and anti-asthmatic segments. In addition to this, it was the first company in Asia to launch a non-CFC metered dose inhaler.
Cipla has not less than 34 state-of-the-art manufacturing facilities that make Active Pharmaceutical Ingredients (APIs) and formulations, which have been approved by major international Regulatory Agencies. Being the manufacturer of over 2000 products in 65 therapeutic categories; with over 40 dosage forms, its products cover a wide spectrum of diseases ranging from communicable, non-communicable, common and emerging diseases to even rare diseases.
With more than seven decades of dedication and service in the field of healthcare, Cipla has secured a global presence in over 170 countries through its exports and strategic alliances. Its exports include raw materials, intermediates, prescription drugs, OTC and veterinary products. The company has partnerships and alliances for product development, technical support and marketing, and is helping several developing countries in their quest for self-reliance. CIPLA is hence known for its uncompromising quality standards in all its products and services, across the world.
- Leader in 8 major respiratory diseases
- 3rd largest producer of MDIs in the world
- 34 internationally approved plants and 65 therapeutic categories